CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced the expansion of its Board of Directors with the appointment of Mr. Nick Leschly, CEO of bluebird bio (NASDAQ: BLUE), Inc., as an independent Director.
